Reported case of severe hepatotoxicity likely due to fluconazole and not desloratadine

Acta Haematologica

Volumn 112, Issue 3, 2004, Pages 177-178

  Kim, Harold ^a,c   Bindslev Jensen, Carsten ^b  

^a GRAND RIVER HOSPITAL   (Canada)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; CIMETIDINE; CLEMASTINE; DESLORATADINE; FLUCONAZOLE; LEVOFLOXACIN; LIVER ENZYME; LORAZEPAM; MACROLIDE; MEROPENEM; RANITIDINE; SPIRONOLACTONE;

CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG WITHDRAWAL; HUMAN; LETTER; LIVER TOXICITY; MYCOSIS; PRIORITY JOURNAL; T CELL LYMPHOMA; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; FLUCONAZOLE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LIVER DISEASES; LORATADINE;

EID: 4644228367     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079733     Document Type: Letter

References (14)

1. Schöttker B, Dösch A, Kraemaer DM: Severe hepatotoxicity after application of desloratadine and fluconazole. Acta Haematol 2003;110:43-44.
2. Bronstein JA, Gros P, Hernandez E, Larroque P, Molinie C: Fatal acute hepatic necrosis due to dose-dependent fluconazole hepatotoxicity. Clin Infect Dis 1997;25:1266-1267.
3. Trujillo MA, Galgiani JN, Sampliner RE: Evaluation of hepatic injury arising during fluconazole therapy. Arch Intern Med 1994;154:102-104.
4. Wells C, Lever AM: Dose dependent fluconazole hepatotoxicity proven on biopsy and rechallenge. J Infect 1992;24:111-112.
5. Fluconazole: Summary of Product Characteristics (http://dok.mpa.se/).
6. Banfield C, Herron J, Keung A, Padhi D, Affrime M: Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet 2002;41(suppl 1):37-44.
7. Banfield C, Hunt T, Reyderman L, Statkevich P, Padhi D, Affrime M: Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet 2002;41(suppl 1):29-35.
8. Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M, Batra V: Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: A randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-466.
9. Desloratadine Summary of Product Characteristics and EMEA Scientific Discussion (http:// www.eudra.org/humandocs/humans/epar/aerius/aerius.htm).
10. Barecki ME, Casciano CN, Johnson WW, Clement RP: In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug Metab Dispos 2001;29:1173-1175.
11. Alverez Lerma F, Gil CL: Clinical experience with meropenem in the treatment of severe infections in critically ill patients. Rev Esp Quimioter 1998;11:229-237.
12. Fisher AA, Le Couteur DG: Nephrotoxicity and hepatotoxicity of histamine H2 receptor antagonists. Drug Saf 2001;24:39-57.
13. Al-Kawas FH, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG: Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann Intern Med 1981;95:588-590.
14. Begaud B, Evreaux JC, Jouglard J, Lagier G: Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie 1985;40:111-118.